GB201906685D0 - Activatable protein constructs and uses thereof - Google Patents

Activatable protein constructs and uses thereof

Info

Publication number
GB201906685D0
GB201906685D0 GBGB1906685.1A GB201906685A GB201906685D0 GB 201906685 D0 GB201906685 D0 GB 201906685D0 GB 201906685 A GB201906685 A GB 201906685A GB 201906685 D0 GB201906685 D0 GB 201906685D0
Authority
GB
United Kingdom
Prior art keywords
protein constructs
activatable protein
activatable
constructs
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1906685.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lockbody Therapeutics Ltd
Original Assignee
Ultrahuman Six Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultrahuman Six Ltd filed Critical Ultrahuman Six Ltd
Priority to GBGB1906685.1A priority Critical patent/GB201906685D0/en
Publication of GB201906685D0 publication Critical patent/GB201906685D0/en
Priority to GBGB1910254.0A priority patent/GB201910254D0/en
Priority to GBGB1917678.3A priority patent/GB201917678D0/en
Priority to GBGB2001196.1A priority patent/GB202001196D0/en
Priority to AU2020276891A priority patent/AU2020276891A1/en
Priority to EP20726749.3A priority patent/EP3969116A1/en
Priority to CN202080034818.9A priority patent/CN113840634B/zh
Priority to SG11202112114YA priority patent/SG11202112114YA/en
Priority to CA3138827A priority patent/CA3138827A1/en
Priority to MX2021013844A priority patent/MX2021013844A/es
Priority to JP2021565875A priority patent/JP7617027B2/ja
Priority to CN202510701821.6A priority patent/CN120554533A/zh
Priority to US17/610,899 priority patent/US20230192899A1/en
Priority to PCT/EP2020/063362 priority patent/WO2020229553A1/en
Priority to KR1020217038644A priority patent/KR20220008841A/ko
Priority to BR112021022661A priority patent/BR112021022661A2/pt
Priority to IL287890A priority patent/IL287890A/en
Priority to JP2025001728A priority patent/JP2025039660A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB1906685.1A 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof Ceased GB201906685D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB1906685.1A GB201906685D0 (en) 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof
GBGB1910254.0A GB201910254D0 (en) 2019-05-13 2019-07-17 Activatable protein constructs and uses thereof
GBGB1917678.3A GB201917678D0 (en) 2019-05-13 2019-12-04 Activatable protein constructs and uses thereof
GBGB2001196.1A GB202001196D0 (en) 2019-05-13 2020-01-28 Activatable protein constructs and uses thereof
BR112021022661A BR112021022661A2 (pt) 2019-05-13 2020-05-13 Anticorpos biespecíficos ativáveis compreendendo um ligante entre os dois domínios de ligação que é uma região de dobradiça de imunoglobulina humana, ou uma variante dela, e usos dos mesmos
CA3138827A CA3138827A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
CN202510701821.6A CN120554533A (zh) 2019-05-13 2020-05-13 可活化蛋白质构建体及其用途
CN202080034818.9A CN113840634B (zh) 2019-05-13 2020-05-13 可活化蛋白质构建体及其用途
SG11202112114YA SG11202112114YA (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
AU2020276891A AU2020276891A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
MX2021013844A MX2021013844A (es) 2019-05-13 2020-05-13 Anticuerpos biespecificos activables que comprenden un enlazador entre los dos dominios de union, que es una region bisagra de inmunoglobulina humana, o una variante de esta, y usos de estos.
JP2021565875A JP7617027B2 (ja) 2019-05-13 2020-05-13 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用
EP20726749.3A EP3969116A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
US17/610,899 US20230192899A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
PCT/EP2020/063362 WO2020229553A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
KR1020217038644A KR20220008841A (ko) 2019-05-13 2020-05-13 인간 면역글로불린 힌지 영역인 두 개의 결합 도메인 사이의 링커 또는 이의 변이체를 포함하는 활성화 가능한 이중특이성 항체 및 이의 용도
IL287890A IL287890A (en) 2019-05-13 2021-11-07 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof
JP2025001728A JP2025039660A (ja) 2019-05-13 2025-01-06 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1906685.1A GB201906685D0 (en) 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof

Publications (1)

Publication Number Publication Date
GB201906685D0 true GB201906685D0 (en) 2019-06-26

Family

ID=67384589

Family Applications (4)

Application Number Title Priority Date Filing Date
GBGB1906685.1A Ceased GB201906685D0 (en) 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof
GBGB1910254.0A Ceased GB201910254D0 (en) 2019-05-13 2019-07-17 Activatable protein constructs and uses thereof
GBGB1917678.3A Ceased GB201917678D0 (en) 2019-05-13 2019-12-04 Activatable protein constructs and uses thereof
GBGB2001196.1A Ceased GB202001196D0 (en) 2019-05-13 2020-01-28 Activatable protein constructs and uses thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
GBGB1910254.0A Ceased GB201910254D0 (en) 2019-05-13 2019-07-17 Activatable protein constructs and uses thereof
GBGB1917678.3A Ceased GB201917678D0 (en) 2019-05-13 2019-12-04 Activatable protein constructs and uses thereof
GBGB2001196.1A Ceased GB202001196D0 (en) 2019-05-13 2020-01-28 Activatable protein constructs and uses thereof

Country Status (13)

Country Link
US (1) US20230192899A1 (enExample)
EP (1) EP3969116A1 (enExample)
JP (2) JP7617027B2 (enExample)
KR (1) KR20220008841A (enExample)
CN (2) CN113840634B (enExample)
AU (1) AU2020276891A1 (enExample)
BR (1) BR112021022661A2 (enExample)
CA (1) CA3138827A1 (enExample)
GB (4) GB201906685D0 (enExample)
IL (1) IL287890A (enExample)
MX (1) MX2021013844A (enExample)
SG (1) SG11202112114YA (enExample)
WO (1) WO2020229553A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3428194T (lt) 2017-07-14 2021-12-10 Immatics Biotechnologies Gmbh Pagerinta dvejopo savitumo polipeptido molekulė
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2022548310A (ja) * 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
US20240002509A1 (en) * 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CA3251615A1 (en) * 2022-01-31 2023-08-03 Centessa Pharmaceuticals (Uk) Limited Activable Bispecific Anti-CD47 and Anti-PD-L1 Proteins and Their Uses
IL315768A (en) * 2022-03-30 2024-11-01 Centessa Pharmaceuticals Uk Ltd Bispecific anti-CD3 and anti-PD-L1 activatable proteins and their uses
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
AU2023271317A1 (en) 2022-05-16 2024-11-07 Byondis B.V. Novel masked antibodies
GB202302074D0 (en) * 2023-02-14 2023-03-29 Creasallis Ltd Agents, methods and uses thereof
WO2024218512A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
EP4698562A1 (en) * 2023-04-19 2026-02-25 Centessa Pharmaceuticals (UK) Limited Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
WO2024241208A1 (ko) * 2023-05-19 2024-11-28 서울대학교산학협력단 Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포
CN121866269A (zh) * 2023-09-14 2026-04-14 Abl生物公司 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法
WO2026038050A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038048A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038047A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
ES2623912T3 (es) 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
MX2017003847A (es) * 2014-09-25 2017-12-15 Amgen Inc Proteinas biespecificas activables por proteasas.
JP7065782B2 (ja) * 2016-03-18 2022-05-12 フレッド ハッチンソン キャンサー リサーチ センター Ｃｄ２０免疫療法のための組成物および方法
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
SG11201909160WA (en) * 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof

Also Published As

Publication number Publication date
WO2020229553A1 (en) 2020-11-19
CN113840634A (zh) 2021-12-24
MX2021013844A (es) 2022-03-17
EP3969116A1 (en) 2022-03-23
JP7617027B2 (ja) 2025-01-17
GB201917678D0 (en) 2020-01-15
CN113840634B (zh) 2025-07-08
BR112021022661A2 (pt) 2022-03-29
GB202001196D0 (en) 2020-03-11
US20230192899A1 (en) 2023-06-22
GB201910254D0 (en) 2019-08-28
CA3138827A1 (en) 2020-11-19
AU2020276891A1 (en) 2021-12-23
IL287890A (en) 2022-01-01
KR20220008841A (ko) 2022-01-21
JP2022532534A (ja) 2022-07-15
CN120554533A (zh) 2025-08-29
JP2025039660A (ja) 2025-03-21
SG11202112114YA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
GB202001196D0 (en) Activatable protein constructs and uses thereof
IL268346A (en) Targeted chimeric proteins and their uses
EP3833391A4 (en) CHIMERIC PROTEINS TARGETED AT SIRP1alpha AND THEIR USES
CA3283159A1 (en) Protein degraders and uses thereof
EP3737666A4 (en) PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CA3247217A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
ZA201900209B (en) Novel natural protein and application thereof
IL300121A (en) Anti-cd93 constructs and uses thereof
SG11202009697RA (en) Micro rna expression constructs and uses thereof
IL288685A (en) Antigen-binding protein structures and uses thereof
IL290279A (en) Implantable structures and their use
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
IL319851A (en) LRRC-15 binding protein structures and uses thereof
SG11202111462VA (en) Asx-specific protein ligases and uses thereof
SG11202104912SA (en) Fusion protein and use thereof
IL272050B1 (en) Synthetic proteins and their therapeutic uses
EP3522907A4 (en) TARGETED EFFECTOR PROTEINS AND USES THEREOF
IL304118A (en) Phrase structures and their uses
IL287601A (en) Variant cd80 proteins and their uses
IL265236A (en) Multipurpose medical buildings and their uses
IL286799A (en) Consolidated structures and their uses
IL311185A (en) MOG-binding proteins and uses thereof
HUP1700012A2 (en) Novel proteins and use thereof
HK40073194A (en) Peptide-mhc ii protein constructs and uses thereof
HK40075761A (en) Antigen-binding protein constructs and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)